NEW YORK, Dec. 11, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Meridian Bioscience, Inc. (NASDAQ:VIVO) who purchased shares between March 25, 2016 and July 13, 2017. The action, which was filed in the United States District Court for the Southern District of Ohio, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Defendant’s lead tests provide inaccurate results; and (ii) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until January 16, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/meridian-bioscience-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Anta Sports Expands Global Footprint With Strategic Puma Stake
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



